**Supplementary Figures**

**Supplementary Figure S2.** Flowchart of patients who were included/excluded from the study.

Endoxifen Analysed (n=247)

Analysed for primary and main secondary endpoint (n=209)

Initial recruitment (n=309)

Enrollment (n=297)

Exclusion (n=12)

Not meeting inclusion criteria

No target lesions (n=38)

No serum material(n=50). Serum sampling was non-compliant with protocol